Shalby Ltd. (SHALBY) AI Stock Analysis

• Market Cap: ₹16.58B
• Dividend Yield: 0.59%
• Average Volume (3M): 71.31K
• Price to Earnings (P/E): 310.4
• Beta (1Y): 1.22
• Revenue Growth: 11.49%
• EPS Growth: -91.65%
• Country: IN
• Employees: 2,853
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.16
• Shares Outstanding: 108,009,766
• 10 Day Avg. Volume: 22,132
• 30 Day Avg. Volume: 71,313
• PEG Ratio: -3.76
• Price to Book (P/B): 2.18
• Price to Sales (P/S): 1.99
• P/FCF Ratio: -21.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 6.1
• Revenue Forecast (FY): ₹13.21B

• Rating: 50 Neutral
• Price Target: ₹127.00 ▼(-37.38% Downside)
• Action: Reiterated Date: 03/05/26
• Date: Action: Reiterated 03/05/26

The score is held back primarily by weak cash flow and a sharp profitability decline, alongside bearish technicals with the stock trading below key moving averages. Strong revenue growth and a relatively solid equity base provide partial support, but valuation is challenging due to an extremely high P/E and only a modest dividend yield.

Positive Factors

Consistent Revenue Growth

Sustained top-line expansion indicates growing patient volumes and increased service uptake across the hospital network. Over 2-6 months this supports capacity utilization, improves bargaining leverage with payors and suppliers, and provides a foundation for reinvestment and scale-driven efficiencies.

Negative Factors

Margin Compression

Sharp contraction in gross and net margins signals rising cost pressures or weaker pricing power. Sustained margin erosion reduces retained earnings available for reinvestment, hurts return on equity, and impairs the company's capacity to fund growth from operating profits over the medium term.

Shalby Ltd. Business Overview & Revenue Model

Company Description

Shalby Limited operates multi-specialty hospitals primarily in India. The company offers arthroscopy, arthroplasty, cardiology, cardiothoracic and vascular surgery, cosmetic and aesthetic, dental cosmetic and implant ology, emergency medicine, end...

Read more

Shalby Limited operates multi-specialty hospitals primarily in India. The company offers arthroscopy, arthroplasty, cardiology, cardiothoracic and vascular surgery, cosmetic and aesthetic, dental cosmetic and implant ology, emergency medicine, end...

How the Company Makes Money

Shalby primarily makes money by delivering hospital services to patients through its network of hospitals. Its revenue model is centered on (1) inpatient services such as admissions, surgeries (including orthopaedic/joint replacement procedures), ...

Read more

Shalby primarily makes money by delivering hospital services to patients through its network of hospitals. Its revenue model is centered on (1) inpatient services such as admissions, surgeries (including orthopaedic/joint replacement procedures), ...

Shalby Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.22B	10.87B	9.34B	8.05B	6.99B	4.31B
Gross Profit	4.00B	2.02B	2.50B	3.70B	3.05B	1.81B
EBITDA	1.60B	1.60B	1.90B	1.61B	1.30B	947.61M
Net Income	44.77M	62.22M	840.77M	677.01M	541.25M	423.96M
Balance Sheet
Total Assets	17.82B	17.04B	16.08B	12.81B	11.94B	9.97B
Cash, Cash Equivalents and Short-Term Investments	1.31B	1.29B	1.08B	2.16B	2.02B	1.29B
Total Debt	5.35B	4.76B	3.78B	1.81B	1.74B	541.27M
Total Liabilities	7.80B	7.08B	6.00B	3.54B	3.17B	1.62B
Stockholders Equity	10.02B	9.92B	10.00B	9.28B	8.76B	8.35B
Cash Flow
Free Cash Flow	-671.45M	-1.03B	-275.11M	492.90M	-564.77M	577.89M
Operating Cash Flow	138.47M	-313.01M	195.96M	677.73M	189.17M	843.49M
Investing Cash Flow	-692.97M	-433.53M	380.73M	-610.59M	-602.82M	-569.70M
Financing Cash Flow	396.33M	822.58M	-1.51B	-500.24M	904.59M	-293.57M

Shalby Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 202.80
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SHALBY, the sentiment is Neutral. The current price of 202.8 is above the 20-day moving average (MA) of 141.56, above the 50-day MA of 153.35, and above the 200-day MA of 196.84, indicating a neutral trend. The MACD of -1.27 indicates Negative momentum. The RSI at 56.72 is Neutral, neither overbought nor oversold. The STOCH value of 86.83 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:SHALBY.

Shalby Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SMSPHARMA	70 Outperform	₹39.30B	29.96	―	0.13%	11.91%	36.92%
VIMTALABS	67 Neutral	₹20.70B	38.21	―	0.16%	17.05%	56.84%
TTKHLTCARE	64 Neutral	₹12.45B	34.84	―	0.95%	6.98%	-17.11%
KRSNAA	58 Neutral	₹19.37B	38.37	―	0.38%	11.51%	21.56%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PANACEABIO	51 Neutral	₹19.73B	144.78	―	―	9.78%	50.78%
SHALBY	50 Neutral	₹16.58B	310.39	―	0.59%	11.49%	-91.65%

Shalby Ltd. Corporate Events